和黄医药(HCM)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

HCM 和黄医药

盘前交易 09-04 05:57:01 EDT

14.11

+2.07

+17.19%

盘前14.50

+0.39+2.79%

05:41 EDT

最高14.23	最低13.51	成交量51.17万
今开13.60	昨收12.04	日振幅5.98%
总市值24.61亿	流通市值14.67亿	总股本1.74亿
成交额711.92万	换手率0.49%	流通股本1.04亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"HCM","market":"US","secType":"STK","nameCN":"和黄医药","latestPrice":14.11,"timestamp":1788465600000,"preClose":12.04,"halted":0,"volume":511724,"hourTrading":{"tag":"盘前","latestPrice":14.5042,"preClose":14.11,"latestTime":"05:41 EDT","volume":1807,"amount":25773.642154,"timestamp":1788514870153,"change":0.3942,"changeRate":0.027938,"amplitude":0.078668},"delay":0,"changeRate":0.17192691029900337,"floatShares":104000000,"shares":174433934,"eps":0.10095,"marketStatus":"盘前交易","change":2.07,"latestTime":"09-04 05:57:01 EDT","open":13.6,"high":14.23,"low":13.51,"amount":7119174.905912001,"amplitude":0.059801,"askPrice":15.63,"askSize":49,"bidPrice":14.01,"bidSize":1,"shortable":3,"etf":0,"ttmEps":0.10095,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1788528600000},"marketStatusCode":1,"adr":1,"adrRate":5,"listingDate":1458187200000,"exchange":"NASDAQ","adjPreClose":14.11,"preHourTrading":{"tag":"盘前","latestPrice":14.5042,"preClose":14.11,"latestTime":"05:41 EDT","volume":1807,"amount":25773.642154,"timestamp":1788514870153,"change":0.3942,"changeRate":0.027938,"amplitude":0.078668},"postHourTrading":{"tag":"盘后","latestPrice":14.0088,"preClose":14.11,"latestTime":"19:31 EDT","volume":2498,"amount":35147.3312,"timestamp":1788478285856,"change":-0.1012,"changeRate":-0.007172,"amplitude":0.007796},"volumeRatio":7.035786372645669,"impliedVol":0.9713,"impliedVolPercentile":0.8526},"requestUrl":"/m/hq/s/HCM","defaultTab":"news","newsList":[{"id":"2664487004","title":"美股异动 | 和黄医药大涨逾14%，与葛兰素史克就癌症药物达成许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2664487004","media":"智通财经","labels":["corporation"],"top":1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664487004?lang=zh_cn&edition=full","pubTime":"2026-09-03 22:54","pubTimestamp":1788447250,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周四，$和黄医药$大涨逾14%。消息面上，和黄医药宣布，附属公司$和记黄埔$医药(上海)与$葛兰素史克$的附属公司达成一项独家开发及许可协议，授予葛兰素史克附属公司除中国内地、香港、澳门和台湾以外的全球范围内开发和商业化HMPL-A830的权利。临床开发将首先聚焦于结直肠癌、胰腺癌和肺癌适应症。","market":"us","thumbnail":"https://static.tigerbbs.com/e8d661c091a8481cd22d8367521ba484","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/e8d661c091a8481cd22d8367521ba484"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491805.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":"和黄医药与葛兰素史克就癌症药物达成许可协议","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","00013","BK1588","BK1587","HCM"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2663044361","title":"五年持续获益！玛伐凯泰最长随访数据公布，进一步证实在oHCM中的长期疗效与安全性","url":"https://stock-news.laohu8.com/highlight/detail?id=2663044361","media":"美通社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663044361?lang=zh_cn&edition=full","pubTime":"2026-08-30 18:09","pubTimestamp":1788084540,"startTime":"0","endTime":"0","summary":"\"EXPLORER-LTE 长达五年的研究数据表明，玛伐凯泰可为有症状的oHCM患者带来持续且具有临床意义的治疗获益。此次ESC大会公布的其他研究结果进一步支持了玛伐凯泰的疗效和安全性，并加深了我们对oHCM疾病影响的理解。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/5035957_ZH35957_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/5035957_ZH35957_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK4149","IHE","LU0456855351.SGD","LU1571399168.USD","BK4007","LU2125154935.USD","IE00BSNM7G36.USD","IE00BJJMRZ35.SGD","IE0002141913.USD","LU2242646821.SGD","LU1074936037.SGD","LU0267386448.USD","LU0225284248.USD","BK4533","BMY","BK4532","LU0203345920.USD","HCM","LU0306806265.USD","MADE","LU2125154778.USD","LU0114720955.EUR","BK4531","LU0069063385.USD","LU0882574055.USD","BK4567","LU2133065610.SGD","LU1093756168.USD","LU1291159041.SGD","LU2463526074.USD","LU1670711123.USD","LU1670711040.USD","CMI","LU0154245756.USD","LU0985481810.HKD","LU0306807586.USD","FTXH","LU1032466523.USD","LU0237698245.USD","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","LU0321505868.SGD","LU1585245621.USD","IE000M9KFDE8.USD","LU1983299246.USD","LU1868837136.USD","LU1718418525.SGD","BK4534","IE00BJT1NW94.SGD","LU0203347892.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660641958","title":"研报掘金丨中金：和黄医药赛沃替尼海外申报现曙光，目标价升至26港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2660641958","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660641958?lang=zh_cn&edition=full","pubTime":"2026-08-19 10:47","pubTimestamp":1787107663,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK1191","BK4585","HCM","BK4531","BK4588","EWH","BK1587","BK1588","BK4007","00013"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660556894","title":"中金：维持和黄医药(00013)跑赢行业评级 上调目标价至26港币","url":"https://stock-news.laohu8.com/highlight/detail?id=2660556894","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660556894?lang=zh_cn&edition=full","pubTime":"2026-08-18 09:12","pubTimestamp":1787015578,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中金发布研报称，基本维持和黄医药2026年/2027年归母净利润预测5,555万美元/8,865万美元不变。该行维持跑赢行业评级，考虑到SAFFRON成功，赛沃替尼海外成功率上调，根据DCF模型，上调目标价9.24%至26港币，较当前股价有29.48%的上行空间。该行认为本次公告PFS和OS均取得阳性结果，有力支撑赛沃替尼在美国等海外核心市场的申报。根据海外合作伙伴阿斯利康中报，其预计有望2H26递交上市申请。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1481153.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HCM","00013"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660364424","title":"美股异动 |  和黄医药(HCM.US)涨近4% SAFFRON III期研究取得积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2660364424","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660364424?lang=zh_cn&edition=full","pubTime":"2026-08-17 23:39","pubTimestamp":1786981164,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4531","III","BK4134","BK4585","BK4588","BK4007","HCM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660810460","title":"和黄医药宣布沃瑞沙®和泰瑞沙®的联合疗法在SAFFRON全球III期研究中显示出具有统计学和临床意义的PFS和OS改善","url":"https://stock-news.laohu8.com/highlight/detail?id=2660810460","media":"美通社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660810460?lang=zh_cn&edition=full","pubTime":"2026-08-17 11:12","pubTimestamp":1786936320,"startTime":"0","endTime":"0","summary":"继SACHI III期研究支持了该疗法在中国获批后，SAFFRON全球研究的结果进一步印证了其坚实的疗效，并将为泰瑞沙和沃瑞沙联合疗法的全球注册提供明确的数据支持。\" 沃瑞沙和泰瑞沙联合疗法的安全性特征与已知的各药物的安全性保持一致，且没有发现新的安全性问题。基于SACHI III期研究，沃瑞沙和泰瑞沙联合疗法已于中国获批用于治疗接受EGFR TKI治疗后疾病进展的伴有MET扩增的EGFR突变的局部晚期或转移性非小细胞肺癌患者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/5027243_ZH27243_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/5027243_ZH27243_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["00013","III","PFS","BK4195","BK4531","BK1191","HCM","BK1587","BK4211","BK4585","BK1588","BK4134","BK4588","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660210915","title":"和黄医药盘中涨近9% 沃瑞沙联合泰瑞沙联合疗法取得积极的顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2660210915","media":"新浪港股","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660210915?lang=zh_cn&edition=full","pubTime":"2026-08-17 10:24","pubTimestamp":1786933440,"startTime":"0","endTime":"0","summary":"沃瑞沙和泰瑞沙联合疗法的安全性特征与已知的各药物的安全性保持一致 ，且没有发现新的安全性问题。基于SACHI III期研究，沃瑞沙和泰瑞沙联合疗法已于中国获批用于治疗接受EGFR TKI治疗后疾病进展的伴有MET扩增的EGFR突变的局部晚期或转移性非小细胞肺癌患者。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-08-17/doc-ininqtnx7878919.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["00013","BK4007","HCM","BK1191","BK1587","BK1588","BK4531","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173380078","title":"港股创新药概念股盘中走强，和黄医药涨超7%，药明生物、金斯瑞生物科技涨超5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1173380078","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1173380078?lang=zh_cn&edition=full","pubTime":"2026-08-17 10:08","pubTimestamp":1786932515,"startTime":"0","endTime":"0","summary":"8月17日，港股创新药概念股盘中走强，$和黄医药(00013)$涨超7%，$药明生物(02269)$、$海西新药(02637)$、$金斯瑞生物科技(01548)$涨超5%，$药明康德(02359)$、$药明合联(02268)$涨超4%，$信达生物(01801)$、$石药集团(01093)$涨超3%。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2097828557.USD","LU0456827905.SGD","BK1610","LU0455707207.USD","LU0572944931.SGD","HCM","SG9999002562.SGD","LU0463099449.HKD","LU1008478684.HKD","BK1588","LU2242644610.SGD","LU1226287875.USD","IE00BZ08YT58.USD","HK0000306685.HKD","01548","LU0128526141.USD","LU0588546209.SGD","BK1589","LU0880133367.SGD","HK0000165453.HKD","LU0359201612.USD","LU0140636845.USD","LU0244354667.USD","LU0979878070.USD","159992","IE00B0JY6N72.USD","LU0051755006.USD","LNGR","LU1969619763.USD","LU0819121731.USD","LU0516423091.SGD","01093","LU0501845795.SGD","LU2328871848.SGD","SG9999014674.SGD","LU1720050803.USD","LU0348735423.USD","HK0000320223.HKD","LU0067412154.USD","06978","LU0327786744.USD","LU1951186391.HKD","LU2045819591.USD","LU2097828631.EUR","LU0348825331.USD","LU1046422090.SGD","LU1688375341.USD","00013","LU0417516738.SGD","LU1807302812.USD","BK4531","IE0008368742.USD","LU0326950275.SGD","LU0072913022.USD","LU1152091168.USD","IE00B543WZ88.USD","LU1226288170.HKD","LU1152091754.HKD","LU0417516902.SGD","LU0359202008.SGD","LU2125910500.SGD","LU0708995583.HKD","IE00BZ08YS42.EUR","IE0008369823.USD","02637","LU1188198961.HKD","KCAI","LU1794554557.SGD","LU0516422366.SGD","BK1574","VXUS","HK0000306701.USD","LU2039709279.SGD","LU1993786604.SGD","SG9999004220.SGD","BK1161","01801","LU0516423174.USD","LU1960683339.HKD","BK1521","02268","BK1141","BK1515","LU1328277881.USD","LU1226287792.SGD","BK4588","IE00B5MMRT66.SGD","LU0502904849.HKD","LU0052750758.USD","LU1242518857.USD","IE00BZ08YR35.GBP","LU0043850808.USD","LU2097828474.EUR","MEDX","LU1880383366.USD","LU0469268626.HKD","IE00B031HY20.USD","LU0320764599.SGD","KURE","BK1576","02359","LU0315179316.USD","LU0823426308.USD","LU0516422952.EUR","LU1226287529.USD","BK1587","BK4585","LU1226288253.USD","LU0314109678.HKD","HK0000320264.USD","LU2097828714.EUR","LU2097828805.USD","LU0856984785.SGD","IBBQ","BK1191","BK1583","BK4007","LU0029874061.USD","LU0348767384.USD","LU0307460666.USD","LU3063872942.SGD","LU1813983027.USD","LU0516422440.USD","LU0039217434.USD","02269","LU2488822045.USD","LU1242518931.SGD","LU0348766576.USD","SG9999002463.SGD","LU0823426480.USD","LU0456846285.SGD","LU0181495838.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660590105","title":"和黄医药(00013.HK)：沃瑞沙® 和泰瑞沙® 的联合疗法在泰瑞沙®治疗后疾病进展的MET驱动的EGFR突变肺癌患者中显示出具有统计学和临床意义的无进展生存期和总生存期改善","url":"https://stock-news.laohu8.com/highlight/detail?id=2660590105","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660590105?lang=zh_cn&edition=full","pubTime":"2026-08-17 08:18","pubTimestamp":1786925918,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4531","LU1989772840.SGD","BK4585","LU1989772923.USD","BK4007","BK4588","LU1291159041.SGD","HCM","LU1989771016.USD","MET","BK4162","LU1496350502.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171302218","title":"新闻稿：Braveheart Bio 宣布扩大规模首次公开募股完成，并完全行使承销商超额配股权","url":"https://stock-news.laohu8.com/highlight/detail?id=1171302218","media":"投资观察","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1171302218?lang=zh_cn&edition=full","pubTime":"2026-08-08 04:09","pubTimestamp":1786133340,"startTime":"0","endTime":"0","summary":"旧金山，2026年8月7日——Braveheart Bio, Inc.是一家临床阶段的生物制药公司，致力于开发针对肥厚型心肌病及其他严重心血管疾病的下一代疗法。该公司今日宣布，其扩大的首次公开募股已完成。此次发行总计24,437,500股普通股，每股发行价为18.00美元，且承销商已完全行使了购买额外3,187,500股的选择权。所有普通股均由Braveheart Bio提供。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0057025933.USD","MADE","BK4585","LU0124676726.USD","LU0154245756.USD","LU0203347892.USD","LU2463526074.USD","LU0154245673.USD","BK4531","BK4567","IPOS","BRVE","BK4588","LU0069063385.USD","BK4149","HCM","CMI","LU0511384066.AUD","LU0289739343.SGD","BK4533","LU0289961442.SGD","LU0472753341.HKD","IE000M9KFDE8.USD","LU0689626769.HKD","BK4007","LU0203345920.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657913306","title":"IDC：2025年中国AI增强HCM市场规模达2.41亿 同比增长505.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2657913306","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657913306?lang=zh_cn&edition=full","pubTime":"2026-08-07 13:38","pubTimestamp":1786081127,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["AIPO","AGIX","QTOC","BK4007","HCM","VTHR","ARTY","BK4588","BK4531","CHAT","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657691332","title":"IDC：2025年中国AI增强HCM市场规模达2.41亿 同比增长505.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2657691332","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657691332?lang=zh_cn&edition=full","pubTime":"2026-08-07 13:38","pubTimestamp":1786081127,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，国际数据公司最新发布的《中国AI增强的人力资本管理市场份额，2025》报告显示，2025年中国AI增强的人力资本管理市场规模达到2.41亿元人民币，同比增长505.7%。市场格局，头部厂商围绕智能化场景、平台与交付能力展开竞争IDC数据显示，2025年中国AI增强HCM市场竞争格局逐渐形成。IDC认为，用友代表了大型集团企业市场中平台型HCM厂商的发展路径，其优势集中体现在复杂组织管理、企业数据基础以及规模化交付能力。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1477197.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VTHR","BK4531","BK4007","QTOC","AIPO","AGIX","ARTY","BK4585","CHAT","BK4588","HCM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657155005","title":"【券商聚焦】申万宏源维持和黄医药（00013）买入评级 指呋喹替尼海外持续放量","url":"https://stock-news.laohu8.com/highlight/detail?id=2657155005","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657155005?lang=zh_cn&edition=full","pubTime":"2026-08-05 14:38","pubTimestamp":1785911894,"startTime":"0","endTime":"0","summary":"金吾财讯 | 申万宏源发布研报指，和黄医药 2026年上半年收入2.78亿美元，同比增长0.2%，净利润为1,600万美元，同比下降96.5%，主因去年同期确认上海和黄药业处置收益，业绩符合预期。呋喹替尼海外市场持续拓展是核心亮点。研报预计，随着市场份额及医保覆盖范围扩大，其海外销售额有望进一步增长。考虑到呋喹替尼海外市场持续放量，申万宏源将26年的每股盈利预测从0.04美元上调至0.06美元，将27年预测从0.08美元上调至0.09美元，新增28年预测为0.10美元。","market":"sg","thumbnail":"https://static.szfiu.com/news/20241108/MjAwMmJhMzhlMzU2ODgyNzA0NzY4MTcyNA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MjAwMmJhMzhlMzU2ODgyNzA0NzY4MTcyNA==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1987535","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HCM","000166","KCE","00013"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656342224","title":"瑞银：降和黄医药(00013)目标价至29.5港元 续予“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2656342224","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656342224?lang=zh_cn&edition=full","pubTime":"2026-08-03 11:24","pubTimestamp":1785727484,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，瑞银发布研报称，和黄医药(00013)上半收入同比增0.2%，大致符合该行预期。肿瘤或免疫业务收入同比增长13%，高于该行预期；纯利1,590万美元，去年同期为4.55亿美元，主要是由于去年同期确认了出售上海医药合营的一次性收益。该行将阿斯利康的里程碑延后至2027年，并修正开支预测，导致2026年的每股盈测下调，而2027年的预测则已由6美仙上调至8美仙。该行将公司目标价由29.7港元下调至29.5港元，续予“买入”评级。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1475127.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HCM","EWH","00013"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656818342","title":"大行评级丨瑞银：微降和黄医药目标价至29.5港元，续予“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2656818342","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656818342?lang=zh_cn&edition=full","pubTime":"2026-08-03 10:57","pubTimestamp":1785725823,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4531","BK4585","00013","BK4007","BK4588","HCM","BK1587","EWH","BK1191","BK1588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655362398","title":"和黄医药发布中期业绩 2026年上半年净利骤降96.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2655362398","media":"经济参考网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655362398?lang=zh_cn&edition=full","pubTime":"2026-07-31 22:06","pubTimestamp":1785506816,"startTime":"0","endTime":"0","summary":"和黄医药（中国）有限公司（简称“和黄医药”，00013.HK）7月30日晚间发布2026年中期业绩公告，上半年公司实现收入总额2.78亿美元，同比增长0.22%；归属于母公司所有者的净利润为1592.80万美元，同比下降96.50%，主要由于2025年同期包含出售上海和黄药业45%股权所得一次性收益4.16亿美元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607313828677510.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607313828677510.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["00013","BK4007","BK1588","BK4585","BK4588","BK4531","BK1587","BK1191","HCM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655938258","title":"粤十数智、星宇股份、汉得信息递表港交所；和黄医药、先声药业、美图公司发布2026年中期业绩预告丨港交所早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2655938258","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655938258?lang=zh_cn&edition=full","pubTime":"2026-07-31 07:01","pubTimestamp":1785452474,"startTime":"0","endTime":"0","summary":"｜2026年7月31日星期五｜NO.1粤十数智、星宇股份、汉得信息递表港交所据港交所7月29日披露，深圳粤十数智股份有限公司（以下简称粤十数智）、常州星宇车灯股份有限公司（以下简称星宇股份，SH601799）、上海汉得信息技术股份有限公司（以下简称汉得信息，SZ300170）已向港交所主板递交上市申请。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607313827197718.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607313827197718.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1587","LU2045819591.USD","BK4585","HCM","00013","BK1588","BK4531","BK1609","BK0188","LU0082770016.SGD","BK0065","IPOS","BK1612","LU2125910849.SGD","BK1191","BK1613","BK1583","300170","BK4007","SG9999006597.SGD","BK4588","IE00B5MMRT66.SGD","IE00B543WZ88.USD","LU0164939612.USD","SG9999001093.SGD","LU2125910500.SGD","02096","BK0231","BK1095","IE00BPRC5H50.USD","BK1618","BK0264","01357","LU0620787316.HKD","601799","LU0082770016.USD","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655874290","title":"和黄医药：2026年上半年净收益为1624万美元 同比降96.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2655874290","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655874290?lang=zh_cn&edition=full","pubTime":"2026-07-30 19:42","pubTimestamp":1785411720,"startTime":"0","endTime":"0","summary":"7月30日，和黄医药（00013/HCM）发布2026年中期业绩，公司收入总额2.78亿美元，同比增长0.22%；净收益为1624万美元，同比减少96.43%；每股普通股基本盈利0.02美元。在管理层讨论与分析中提到，爱优特?和苏泰达?的强劲市场销售反映了公司商业团队针对中国市场监管指引变化所采取的有效措施。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607303826904289.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607303826904289.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4531","BK1587","BK1191","BK1588","00013","BK4585","BK4588","BK4007","HCM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655767578","title":"和黄医药：2026年上半年净收益1590万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2655767578","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655767578?lang=zh_cn&edition=full","pubTime":"2026-07-30 19:03","pubTimestamp":1785409407,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4585","BK4588","BK4007","BK4531","HCM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159471825","title":"财报前瞻｜和黄医药本季度营收暂无一致预测，机构观点偏中性观望","url":"https://stock-news.laohu8.com/highlight/detail?id=1159471825","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1159471825?lang=zh_cn&edition=full","pubTime":"2026-07-24 05:02","pubTimestamp":1784840578,"startTime":"0","endTime":"0","summary":"和黄医药将在2026年07月30日发布最新财报，市场对营收和盈利的短期趋势仍在消化，关注核心商业化进展与研发资本开支节奏。目前未获得覆盖期内可用的一致预测及公司对本季度收入、毛利率、净利润或净利率、调整后每股收益的量化指引数据，相关机构仍待公司在财报披露时提供更清晰的展望。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"财报前瞻｜和黄医药本季度营收暂无一致预测，机构观点偏中性观望","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HCM"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.hutch-med.com","stockEarnings":[{"period":"1week","weight":0.1365},{"period":"1month","weight":0.2195},{"period":"3month","weight":0.2981},{"period":"6month","weight":0.0188},{"period":"1year","weight":-0.076},{"period":"ytd","weight":0.0585}],"compareEarnings":[{"period":"1week","weight":0.0027},{"period":"1month","weight":0.0024},{"period":"3month","weight":0.0483},{"period":"6month","weight":0.1499},{"period":"1year","weight":0.2011},{"period":"ytd","weight":0.1338}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"和黄医药（中国）有限公司是一间主要从事制造及销售药物的投资控股公司。该公司主要通过两个分部运营业务。肿瘤免疫业务分部从事发现、开发和商业化用于治疗癌症和免疫性疾病的靶向疗法和免疫疗法。其中研发包括涵盖药物发现、开发、生产及监管职能的研发活动，上市产品包括通过研发活动开发的药物的已开具发票的销售、推广、生产及分销。其他业务分部从事其他商业化业务，包括其他处方药物及保健品的销售、推广、生产及分销。","yearOnYearQuotes":[{"month":1,"riseRate":0.3,"avgChangeRate":-0.03068},{"month":2,"riseRate":0.4,"avgChangeRate":0.01065},{"month":3,"riseRate":0.4,"avgChangeRate":-0.00847},{"month":4,"riseRate":0.454545,"avgChangeRate":0.024272},{"month":5,"riseRate":0.363636,"avgChangeRate":-0.076728},{"month":6,"riseRate":0.636364,"avgChangeRate":0.064917},{"month":7,"riseRate":0.636364,"avgChangeRate":0.05138},{"month":8,"riseRate":0.454545,"avgChangeRate":0.010337},{"month":9,"riseRate":0.545455,"avgChangeRate":-0.001105},{"month":10,"riseRate":0.5,"avgChangeRate":-0.007604},{"month":11,"riseRate":0.7,"avgChangeRate":0.110086},{"month":12,"riseRate":0.5,"avgChangeRate":-0.016892}],"exchange":"NASDAQ","name":"和黄医药","nameEN":"Hutchison China Meditech"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"和黄医药(HCM)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供和黄医药(HCM)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"和黄医药,HCM,和黄医药股票,和黄医药股票老虎,和黄医药股票老虎国际,和黄医药行情,和黄医药股票行情,和黄医药股价,和黄医药股市,和黄医药股票价格,和黄医药股票交易,和黄医药股票购买,和黄医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"和黄医药(HCM)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供和黄医药(HCM)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}